Meeting
2019 ASCO Annual Meeting
Exploration of tumor genetic alterations and associations with clinical outcomes: Retrospective genomic analysis of archived liposarcoma (LPS) and leiomyosarcoma (LMS) samples from phase III trial of trabectedin (T) versus dacarbazine (D).
Authors
Shibu Thomas
Janssen Research and Development, Spring House, PA
Shibu Thomas , Shilpy Joshi , Dong Shen , Roland Elmar Knoblauch , Michael Gormley , George C. Wang , Deborah S. Ricci , Clifford Motley , Robert G. Maki , Margaret von Mehren , Shreyaskumar Patel , George D. Demetri
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Citation
J Clin Oncol 37, 2019 (suppl; abstr 11019)
DOI
10.1200/JCO.2019.37.15_suppl.11019
Abstract #
11019
Poster Bd #
342
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Whole exome sequencing (WES) of metastatic leiomyosarcoma (LMS) and liposarcoma (LPS) and correlation of genomic aberrations with clinical outcomes in the phase III randomized trial of trabectedin (T) vs. dacarbazine (D).
First Author: Gurpreet Kapoor
Poster
2016 ASCO Annual Meeting
Subtype-specific activity in liposarcoma (LPS) patients (pts) from a phase 3, open-label, randomized study of eribulin (ERI) versus dacarbazine (DTIC) in pts with advanced LPS and leiomyosarcoma (LMS).
First Author: Sant P. Chawla
Poster
2023 ASCO Annual Meeting
SARC041: A phase 3 randomized double-blind study of abemaciclib versus placebo in patients with advanced dedifferentiated liposarcoma.
First Author: Mark Andrew Dickson
Poster
2016 ASCO Annual Meeting
Patient-reported outcomes from randomized, phase-3 study of trabectedin (T) vs. dacarbazine (D) in advanced leiomyosarcoma (LMS) or liposarcoma (LPS).
First Author: George D. Demetri